AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models-Reference-Cited by-同舟云学术

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models

Published:2016-03-28 Issue:11 Volume:76 Page:3307-3318
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Weir Hazel M.,Bradbury Robert H.,Lawson Mandy,Rabow Alfred A.,Buttar David,Callis Rowena J.,Curwen Jon O.,de Almeida Camila,Ballard Peter,Hulse Michael,Donald Craig S.,Feron Lyman J.L.,Karoutchi Galith,MacFaul Philip,Moss Thomas,Norman Richard A.,Pearson Stuart E.,Tonge Michael,Davies Gareth,Walker Graeme E.,Wilson Zena,Rowlinson Rachel,Powell Steve,Sadler Claire,Richmond Graham,Ladd Brendon,Pazolli Ermira,Mazzola Anne Marie,D'Cruz Celina,De Savi Chris

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23

2. Selective Estrogen Receptor Degraders (SERDs);Current Breast Cancer Reports;2024-07-26

3. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models;Clinical Cancer Research;2024-05-31

4. Metabolism-driven in vitro/in vivo disconnect of an oral ERɑ VHL-PROTAC;Communications Biology;2024-05-13

5. Mapping the 5-HTergic neural pathways in perimenopausal mice and elucidating the role of oestrogen receptors in 5-HT neurotransmission;Heliyon;2024-03